Showing results (491-500 of 510) with videos related to

Sort By:
Pageof 51
Plos One|May 13, 2024
Evidence of reassortment of avian influenza A (H2) viruses in Brazilian shorebirdsLuciano M Thomazelli, João Renato Rebello Pinho, Erick G Dorlass, et al.
Scientific Reports|January 19, 2017
The clinically approved antiviral drug sofosbuvir inhibits Zika virus replicationCarolina Q Sacramento, Gabrielle R de Melo, Caroline S de Freitas, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 31, 2022
Effectiveness of Heterologous Coronavirus Disease 2019 (COVID-19) Vaccine Booster Dosing in Brazilian Healthcare Workers, 2021Alexandre R Marra, João Luiz Miraglia, Daniel Tavares Malheiros, et al.
Infection Control and Hospital Epidemiology|March 30, 2022
Effectiveness of two coronavirus disease 2019 (COVID-19) vaccines (viral vector and inactivated viral vaccine) against severe acute respiratory coronavirus virus 2 (SARS-CoV-2) infection in a cohort of healthcare workersAlexandre R Marra, João Luiz Miraglia, Daniel Tavares Malheiros, et al.
Rheumatology Advances in Practice|April 1, 2024
Coalition for Health and Gender Equity (CHANGE)-a protocol for a global cross-sectional survey of health and gender equity in rheumatologyTayyeba Khursheed, Pavel Ovseiko, Sarah Dyball, et al.
Plos Neglected Tropical Diseases|January 31, 2019
Yellow fever virus is susceptible to sofosbuvir both in vitro and in vivoCaroline S de Freitas, Luiza M Higa, Carolina Q Sacramento, et al.
Lancet Regional Health. Americas|February 13, 2023
Ambulatory and hospitalized patients with suspected and confirmed mpox: an observational cohort study from BrazilMayara Secco Torres Silva, Carolina Coutinho, Thiago Silva Torres, et al.
Antimicrobial Stewardship & Healthcare Epidemiology : ASHE|July 3, 2023
Longer-term effectiveness of a heterologous coronavirus disease 2019 (COVID-19) vaccine booster in healthcare workers in BrazilAlexandre R Marra, João Luiz Miraglia, Daniel Tavares Malheiro, et al.
Infection Control and Hospital Epidemiology|June 5, 2023
Risk factors for long coronavirus disease 2019 (long COVID) among healthcare personnel, Brazil, 2020-2022Alexandre R Marra, Vanderson Souza Sampaio, Mina Cintho Ozahata, et al.
Eclinicalmedicine|April 16, 2025
Caplacizumab use in immune-mediated thrombotic thrombocytopenic purpura: an international multicentre retrospective Cohort study (The Capla 1000+ project)Paul Coppo, Michael Bubenheim, Ygal Benhamou, et al.
Pageof 51